Physician profile
Mark A Risen
NPI 1174571004
$2,146.73
in general payments reported to CMS, 2019-2025
33 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $170 · 2021: $279 · 2022: $295 · 2023: $288 · 2024: $286 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Trilliant Surgical LLC. | $442.93 | 2019 | |
| Organogenesis INC. | $238.36 | 2022-2025 | Cygnus Dual, Puraply |
| Abbott Laboratories | $109.79 | 2021-2025 | Proclaim |
| Reprise Biomedical, INC. | $106.30 | 2024-2025 | Miro3d |
| Novo Nordisk INC | $105.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bsn Medical INC | $98.21 | 2023 | |
| Abbvie INC. | $91.72 | 2021-2023 | Dalvance |
| Rikco International, LLC | $88.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.15 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $75.30 | 2019-2022 | |
| Horizon Therapeutics Plc | $67.20 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.42 | 2021-2022 | |
| Pfizer INC. | $58.52 | 2020-2021 | |
| Corcept Therapeutics | $54.91 | 2025 | Korlym |
| Convatec INC. | $52.07 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $51.64 | 2022-2023 | Livalo, Seglentis |
| Amarin Pharma, INC. | $39.61 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $38.18 | 2019-2021 | |
| Averitas Pharma INC. | $33.10 | 2025 | Qutenza |
| Urgo Medical North America, LLC | $25.49 | 2023 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Paratek Pharmaceuticals, INC. | $25.44 | 2025 | Nuzyra |
| Pacira Pharmaceuticals Incorporated | $24.86 | 2024 | Exparel |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.25 | 2022 | |
| Amgen INC. | $22.16 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $18.51 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $18.24 | 2023 | Gvoke Hypopen |
| Smith+Nephew, INC. | $14.21 | 2022 | |
| Radius Health, INC. | $13.84 | 2023 | Tymlos |
| Glaxosmithkline, LLC. | $13.20 | 2023 | Arexvy, Trelegy Ellipta |
| Nabriva Therapeutics, Plc | $13.12 | 2021 | |
| Insulet Corporation | $12.56 | 2022 | |
| Allergan, INC. | $11.16 | 2020 | |
| Lilly USA, LLC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Risen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.